

to
> get things done (i.e. to offset interference in their regular work
> routines). (Rich needs to verify whether existing budget adequately
> covers this).
>
> (e) Otto would be the best person to address the power issue on the CC/DP
> side. On the ME side, the lower than expected prevalence of Bz exposure
> has certainly increased the effort required to recruit factories.
>
> (f) (BTEX): Regarding ME phase 1 only, we estimated that an additional
70K
> would be needed to analyze T and X as well as Bz. If we want to make T
and
> X a focus of phase2, much more work is needed, especially if we want to
> analyze compound-specific metabolites... You and Otto ought to consider
the
> scope needed to elevate focus on T and X in CC/DP.
>
> Finally, I assume that the technical committee has asked Fu this very
> question (e.g. last chance for budget increase). Michael - please
verify.
> If not, do you want our team to coordinate this with our Chinese
> colleagues??
>
> Rob
>
> A. Robert Schnatter
> Senior Scientific Advisor
> ExxonMobil Biomedical Sciences, Inc.
> Room LF-246
> 1545 Route 22 East
> Annandale, NJ 08801-0971
> 908-730-1101

-----Original Message-----

From: Bruce Jarnot
Sent: Wednesday, April 06, 2005 3:07 PM
To: 'benzconsort-tc@listserv.api.org'
Cc: Lorraine Twerdok
Subject: SHS... FYI: confirming EMBSI budget reanalysis

FYI... for budget reanalysis discussion on Friday's TC call.

-----Original Message-----

From: a.r.schnatter@exxonmobil.com [mailto:a.r.schnatter@exxonmobil.com]
Sent: Wednesday, April 06, 2005 12:38 PM
To: Bruce Jarnot
Subject: budget issues.

Bruce - regarding your voice mail -- I am working this from two perspectives: our existing budget request and also exposure assessment activities that may have fallen through the cracks for existing budget requests. Regarding EMBSI, our request of 884K is still likely to be OK. Regarding the second item, some needed activities do not appear to be in anyone's existing budget: e.g. an extension for Dr. Ni, who is instrumental

in identifying ME factories, and perhaps expected payments to those factories. We are waiting for some answers from Yimei on certian items -- will try to get you numbers around any addtional considerations by end-of-week.

Regards,
Rob

A. Robert Schnatter
Senior Scientific Advisor
Exxon Mobil Biomedical Sciences, Inc.
Room LF-246
Route 22 East
Annadale, NJ 08801-0971
908-730-1101
908-730-1192(fax)
